Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2013-02-08 Regulatory Filings
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2013
Regulatory Filings
2013-02-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically discusses the setting of the date for the company's fiscal 2013 Annual Meeting of Stockholders and related shareholder director nomination deadlines. It does not contain financial statements or detailed financial performance data, nor is it a proxy statement or voting results announcement. The document is relatively short (2949 characters) and serves as a notification of an event rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2013-01-22 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 28, 2012. The content focuses on the approval of base salaries and bonuses for the CEO and CFO, including stock compensation details. This corresponds to announcements about changes in senior management compensation and appointments. There is no financial performance data, earnings information, or detailed report content. The document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management, including compensation changes. The document length is short and specific to management compensation, not a full report or earnings release.
2013-01-03 English
OWNERSHIP DOCUMENT
Director's Dealing
2013-01-03 English
OWNERSHIP DOCUMENT
Director's Dealing
2013-01-03 English
OWNERSHIP DOCUMENT
Director's Dealing
2012-12-12 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.